November 12th, 2026Shifting From Late Rescue to Early COPD Detection and CareExperts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.Read more
November 10th, 2026How Plans, Clinicians Should Handle Gray-Market RetatrutideIn this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.Read more
November 7th, 2026Health Care Disparities Persist Across Liver DiseasesLiver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026. Read more
November 12th, 2026Phase 3 Trial Tests Ensifentrine for COPD Exacerbation PreventionMerck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.Read more
November 12th, 2026Oral Enlicitide Could Close Primary Prevention Gap: Christie Ballantyne, MDIn this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.Read more
November 12th, 2026Commentary Warns Census Race Question Removal Could Create Data GapProposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.Read more
November 12th, 2026The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH CostsPhase 3 hepatitis delta data, MASH persistence and cost findings, and new PBC treatment targets led The Liver Meeting 2026 in Denver, Colorado.Read more
November 12th, 2026Bronchiectasis Prevalence Rises in All Payers as Incidence Stays FlatNon-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.Read more